Female embryonic lethality in mice nullizygous for both Msh2 and p53

Nature Genetics

Volumn 17, Issue 1, 1997, Pages 114-118

  Cranston, Aaron ^a   Bocker, Tina ^a   Reitmair, Armin ^b,d   Palazzo, Juan ^c   Wilson, Teresa ^a   Mak, Tak ^b   Fishel, Richard ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASE MISPAIRING; CARCINOGENESIS; CONTROLLED STUDY; DNA REPAIR; EMBRYO; EMBRYO DEATH; FEMALE; LETHALITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; TUMOR SUPPRESSOR GENE;

ANIMALS; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; FETAL DEATH; FETAL RESORPTION; GENES, P53; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICROSATELLITE REPEATS; MUTS HOMOLOG 2 PROTEIN; PREGNANCY; PROBABILITY; PROTO-ONCOGENE PROTEINS; SEX CHARACTERISTICS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; ESCHERICHIA;

EID: 0030814494     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng0997-114     Document Type: Article

References (29)

1. Loeb, L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51, 3075-3079 (1991).
2. Fishel, R. & Wilson, T. MutS homologs in mammalian cells. Curr. Opin Genet Dev. 7, 105-113 (1997).
3. Fishel, R. et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer [published erratum appears in Cell 77, 1994]. Cell 75, 1027-1038 (1993).
4. Nyström Lahti, M. et al. Mismatch repair genes on chromosomes 2p and 3p account for a major share of hereditary nonpolyposis colorectal cancer families evaluable by linkage. Am. J. Hum. Genet 55, 659-665 (1994).
5. Kastan, M.B. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597 (1992).
6. Fearon, E. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
7. de Wind, N., Dekker, M., Berns, A., Radman, M. & te Riele, H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82, 321-330 (1995).
8. Reitmair, A.H. et al. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nature Genet 11, 64-70 (1995).
9. Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
10. Jacks, T. et al. Tumor spectrum analysis in p53-mutarit mice. Curr. Biol. 4, 1-7 (1994).
11. Purdie, C.A. et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9, 603-609 (1994).
12. Sah, V.P. et al. A subset of p53-deficient embryos exhibit exencephaly. Nature Genet. 10, 175-180 (1595).
13. Nicol, C.J., Harrison, M.L., Laposa, R.R., Gimelshtein, I.L. & Wells, P.G. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nature Genet 10, 181-187 (1995).
14. Blyth, K. et al. Synergy between a human c-myctransgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene 10, 1717-1723 (1995).
15. Williams, B.O., Morgenbesser, S.D., DePinho, R.A. & Jacks, T. Tumorigenic and developmental effects of combined germ-line mutations in Rb and p53. Cold Spring Harbor Symp. Quant Biol. 59, 449-457 (1994).
16. Williams, B.O. et al. Cooperative tumorigenic effects of germline mutations in Rb and p53. Cell 79, 329-339 (1994).
17. Donehower, L.A. et al. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 9, 882-895 (1995).
18. Nacht, M. et al. Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev. 10, 2055-2066 (1996).
19. Lyon, M.F. Gene action in the X chromosome of the mouse (Mus musculus L). Nature 190, 372-373 (1961).
20. Rastan, S. X chromosome inactivation and the Xist gene. Curr. Opin. Genet Dev. 4, 292-297 (1994).
21. Theiler, K. The House Mouse Development and Normal Stages from Fertilization to 4 Weeks of Age, 168 (Springer-Verlag, New York, 1972).
22. Taylor, J.H. Asynchronous replication of chromosomes in cultured cells of Chinese hamster. J. Biophys. Biochem. Cytol. 7, 455-464 (1960).
23. Tagaki, N. Differentiation of the X chromosomes in early female mouse embryos. Exp. Cell Res. 86, 127-135 (1974).
24. Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K. & Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912-915 (1990).
25. Diller, L. et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10, 5772-5781 (1990).
26. Lin, D., Shields, M.T., Ullrich, S.J., Appella, E. & Mercer, W.E. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc. Natl. Acad. Sci. USA 89, 9210-9214 (1992).
27. Hawn, M.T. et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint Cancer Res. 55, 3721-3725 (1995).
28. Marra, G. et al. Expression of human Muts homolog 2 (hMSH2) protein in resting and proliferating cells. Oncogene 13, 2189-2196 (1996).
29. Rogel, A., Popliker, M., Webb, C.G. & Oren, M. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mot. Cell. Biol. 5, 2851-2855 (1985).